NCT01722162View on ClinicalTrials.gov

Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Colorectal Neoplasms
Interventions
DRUG

Bevacizumab

DRUG

Capecitabine

DRUG

Levocetirizine

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT01722162 - Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | Biotech Hunter | Biotech Hunter